Brigham and Women’s Gives Cancer Researchers Access to HistoRx’s Aqua
Brigham and Women’s Hospital will make HistoRx’s Aqua technology for protein biomarker profiling available to more than 900 Dana-Farber/Harvard Cancer Center scientists serviced by the facility, HistoRx said last week.
The pathology core facility at Brigham is a service hub that provides tissue-based tests and analysis to investigators at DF/HCC institutions, and is using the Aqua technology to identify and quantify protein biomarkers in tissue samples for researchers doing work in cancer diagnostics and drug development.
The facility bought a HistoRx PM-2000 tissue analysis platform instrument, which incorporates the Aqua technology, in 2005.
Eppendorf Deal Gives Gentel Customers Access to Protein Analysis Tools
German life science tools firm Eppendorf will provide Gentel Biosciences customers “ultra-sensitive” multiplexed protein analysis tools using colorimetric detection and Eppendorf’s proprietary nitrocellulose films, under a global licensing deal announced this week.
Under the agreement Gentel will license Eppendorf’s Silverquant colorimetric detection technology for use in protein detection arrays. Silverquant technology uses gold particle-enhanced silver crystal deposition for detection and quantification on microarrays.
Terms of the deal were not disclosed.
Proteomika, Auguron Ink Deal for NAPPA technology
Proteomika will have access to Auguron’s Nucleic Acid Programmable Protein Array technology under an option agreement announced this week.
Under the agreement, Proteomika can manufacture and use NAPPA technology at its facilities for Proteomika’s internal purposes and the provision of services to the company’s partners.
Proteomika also has the option to negotiate a license agreement for the use of the technology for biomarker discovery for inflammatory bowel disease and lupus.
Terms of the agreement were not disclosed.
Based in Spain, Proteomika is a subsidiary of Progenika Biopharma, a personalized medicine firm. Auguron was co-founded late last year by Joshua LaBaer, head of Harvard Medical School’s Institute of Proteomics, to commercialize the NAPPA technology.
Nonlinear to Distribute GeneBio’s Phenyx Software
Nonlinear Dynamics will distribute Geneva Bioinformatics’ Phenyx MS identification platform under a worldwide distribution agreement announced this week.
The deal allows Nonlinear to distribute Phenyx as a stand-alone software package or alongside Nonlinear’s Progenesis LC-MS software for label-free quantitative analysis.
Financial terms of the agreement were not disclosed.
GeneGo, Merck Extend Deal
GeneGo said this week it’s global enterprise agreement with Merck has been extended.
The deal gives Merck access to GeneGo’s content through MetaBase, which includes access to MetaCore and DetaDrug content as well as the company’s internal database of disease markers.
Financial details were not disclosed.
Hybregnics Renews Contract with Servier
French bio-pharmaceuticals company Hybrigenics said this week it has renewed a contract with Servier Laboratories for the validation of ubiquitin-specific protease involved in the regulation of an undisclosed cancer-related protein.
If the current work is successful, Hybrigenics will develop an assay to screen small molecules for the inhibition of the protein.